A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)
Public ClinicalTrials.gov record NCT00168857. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare MICARDIS® (Telmisartan) 80 mg Versus COZAAR® (Losartan) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A number of blood pressure lowering drugs in the class known as angiotensin receptor blockers (ARB) have been shown to slow the decline in kidney function of patients with type 2 diabetes, high blood pressure, and kidney disease. Losartan (COZAAR), is one such drug. The purpose of this research study is to determine if after one year of treatment telmisartan (MICARDIS, GLIOSARTAN, KINZAL, KINZALMONO, PREDXAL, PRITOR, SAMERTAN, TELMISARTAN) 80 mg, another blood pressure lowering drug from the ARB class, is as effective as losartan (COZAAR) 100 mg in reducing the level of urinary protein (indicative of improved kidney function).
Study identification
- NCT ID
- NCT00168857
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 860 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 21 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 9, 2003 (Actual)
- Primary completion
- Jun 1, 2006 (Actual)
- Completion
- Not listed
- Last update posted
- Dec 8, 2023
Started 2003
United States locations
- U.S. sites
- 47
- U.S. states
- 23
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Boehringer Ingelheim Investigational Site | Montgomery | Alabama | — | — |
| Boehringer Ingelheim Investigational Site | Little Rock | Arkansas | — | — |
| Boehringer Ingelheim Investigational Site | Lancaster | California | — | — |
| Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| VA of Greater Los Angeles | Los Angeles | California | — | — |
| UCI Medical Center | Orange | California | — | — |
| VA San Diego Healthcare System | San Diego | California | — | — |
| Boehringer Ingelheim Investigational Site | Santa Ana | California | — | — |
| UCLA Medical Center | Sylmar | California | — | — |
| Torrance Clinical Research | Torrance | California | — | — |
| University of Colorado Health Sciences Center | Denver | Colorado | — | — |
| Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| George Washington University | Washington D.C. | District of Columbia | — | — |
| Boehringer Ingelheim Investigational Site | Hollywood | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Largo | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Ocala | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| Medical College of Georgia | Augusta | Georgia | — | — |
| Rush Presbyterian - St. Lukes Medical Center | Chicago | Illinois | — | — |
| Boehringer Ingelheim Investigational Site | Des Moines | Iowa | — | — |
| Louisiana State University Health Science Center | New Orleans | Louisiana | — | — |
| Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | — | — |
| Boehringer Ingelheim Investigational Site | Towson | Maryland | — | — |
| Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| Boehringer Ingelheim Investigational Site | Springfield | Massachusetts | — | — |
| Boehringer Ingelheim Investigational Site | Eatontown | New Jersey | — | — |
| University of Medicine and Dentistry of New Jersey | Newark | New Jersey | — | — |
| Boehringer Ingelheim Investigational Site | Flushing | New York | — | — |
| Winthrop University Hospital | Mineola | New York | — | — |
| Harlem Hospital | New York | New York | — | — |
| Northport VAMC - Medical Service (111) | Northport | New York | — | — |
| Wake Nephrology Associates, PA | Raleigh | North Carolina | — | — |
| The Cleveland Foundation | Cleveland | Ohio | — | — |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | — | — |
| Temple University Hospital | Philadelphia | Pennsylvania | — | — |
| VA Pittsburgh Healthcare System | Pittsburgh | Pennsylvania | — | — |
| Medical University of South Carolina | Charleston | South Carolina | — | — |
| The University of Texas Southwestern Medical Center | Dallas | Texas | — | — |
| Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| University of Texas Health and Science Center at San Antonio | San Antonio | Texas | — | — |
| University of Vermont | Burlington | Vermont | — | — |
| University of Virginia Health Science Center | Charlottesville | Virginia | — | — |
| Boehringer Ingelheim Investigational Site | Gig Harbor | Washington | — | — |
| Boehringer Ingelheim Investigational Site | Seattle | Washington | — | — |
| Clement J. Zablocki Veterans Administration Medical Center | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00168857, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 8, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00168857 live on ClinicalTrials.gov.